Taking Aim at the TYK2 Pathway in Psoriasis

Drs. Armstrong & Gordon discuss the latest psoriasis updates from #AAD2021 https://bit.ly/3mr1ftOПодробнее

TYK2 Inhibitors for the Treatment of Psoriasis | Ronald Vender, MD, FRCPC | CanadaПодробнее

Realizing the Potential of TYK2 Inhibition to Address the Burden of PsoriasisПодробнее

TYK2 Inhibitor_AZothBioПодробнее

The TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option in Moderate to Severe PsoriasisПодробнее

Finding the Right Pathway in Psoriasis: TYK2 as a Therapeutic Target in Real-World PracticeПодробнее

Fine-Tuning the JAK/STAT Pathway in PsoriasisПодробнее

From Pathophysiology to Therapeutic Progress: TYK2's Significance in Plaque PsoriasisПодробнее

TYK2 Inhibitors Show Efficacy in Psoriatic Arthritis - Medpage TodayПодробнее

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumabПодробнее

Psoriasis and IBD: Overlapping Pathways and Treatment Considerations | Lev Pavlovsky, MD, PhDПодробнее

IL-17 family cytokines involved in psoriasis, M.A.X. Tollenaere et alПодробнее

IL-23s: Psoriasis therapy overviewПодробнее

Refining Treatment Targets for the Management of PsoriasisПодробнее

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, trial in psoriatic arthritisПодробнее

Applying the Psoriasis Guidelines to PracticeПодробнее

Psoriasis Treatment Pathways with Professor Catherine SmithПодробнее

Psoriasis and beyond: targeting the IL-17 pathwayПодробнее

New Psoriasis Treatments: JAK Inhibitors, TYK2 Inhibitors... | What's New for Psoriasis TreatmentsПодробнее